APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

12 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

05 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

26 Oct 2024 14:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

22 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

16 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

25 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

20 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Aug 2024 16:05:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

01 Aug 2024 07:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

18 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

09 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

28 Jun 2024 06:57:12 By Nasdaq GlobeNewswire

SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)

10 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

05 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

24 May 2024 10:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street

14 May 2024 08:00:00 By Nasdaq GlobeNewswire